Secukinumab
- CAS No.
- 875356-43-7
- Chemical Name:
- Secukinumab
- Synonyms
- Secukinuma;Secukinumab/Secukinumab(Hchain)
- CBNumber:
- CB24662444
- Molecular Formula:
- Molecular Weight:
- 0
- MOL File:
- Mol file
- Modify Date:
- 2023/5/9 9:30:36
Secukinumab Chemical Properties,Uses,Production
Mechanism of action
Secukinumab is unique from other approved therapies for psoriasis as it is a first-in-class recombinant high-affinity, fully human monoclonal antibody of the IgG1/kappa isotype that selectively targets IL-17A. Secukinumab interferes in the psoriasis pathologic process by selectively binding to IL-17A, thereby preventing IL-17A interaction with the IL-17 receptor expressed on, for example, keratinocytes[1].
Pharmacokinetics
Secukinumab's pharmacokinetics (PK) profile is typical of a fully human immunoglobulin IgG1 molecule: Slow subcutaneous (SC) absorption, low clearance, and long half-life. Clearance of secukinumab in geriatric patients and patients <65 years of age was similar. Because secukinumab is a human IgG with a large molecular size (~150 kDa) and because intact immunoglobulin is filtered by the kidney to a minimal degree, only very small amounts of antibody are expected to be excreted in the urine. Thus, renal impairment is not likely to influence urinary excretion and the overall PK profile. Finally, hepatic impairment would not be expected to influence the metabolism or excretion of human IgG. Secukinumab's main route of elimination is through intracellular catabolism. Thus, the potential for drug interactions between secukinumab and small drug molecules is low.
References
[1] Godse, Kiran. “Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis.” Indian Journal of Dermatology 62 2 (2017): 195–199.
Secukinumab Preparation Products And Raw materials
Raw materials
Preparation Products
Secukinumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Shanghai Minbiotech Co., Ltd. | +8617315815539 | CHINA | 129 | 58 | Inquiry |
| AFINE CHEMICALS LIMITED | +86-0571-85134551 | China | 15395 | 58 | Inquiry |
| Baoji Guokang Healthchem co.,ltd | +8615604608665 15604608665 | CHINA | 9427 | 58 | Inquiry |
| Nantong HI-FUTURE Biology Co., Ltd. | +undefined18051384581 | China | 3136 | 58 | Inquiry |
| TargetMol Chemicals Inc. | +1-781-999-5354 | United States | 19973 | 58 | Inquiry |
| LEAPCHEM CO., LTD. | +86-852-30606658 | China | 43348 | 58 | Inquiry |
| Wuhan Jingkang en Biomedical Technology Co., Ltd | +8613720134139 | China | 4692 | 58 | Inquiry |
| Olix (Shanghai) Pharmaceutical Technology Co., Ltd | 17316404525 | China | 9640 | 58 | Inquiry |
| Hubei wei shi reagent group ltd., company | 027-59105166 13125137732 | China | 2983 | 58 | Inquiry |
| Hubei wei shi reagent group ltd., company | 027-59102966 18627096350 | China | 2829 | 58 | Inquiry |